Akita RW - Search Results

1

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. Agus DB, et al. Among authors: akita rw. Cancer Cell. 2002 Aug;2(2):127-37. doi: 10.1016/s1535-6108(02)00097-1. Cancer Cell. 2002. PMID: 12204533 Free article.

2

A potential role for activated HER-2 in prostate cancer.

Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX. Agus DB, et al. Among authors: akita rw. Semin Oncol. 2000 Dec;27(6 Suppl 11):76-83; discussion 92-100. Semin Oncol. 2000. PMID: 11236032 Review.

3

Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association.

Penuel E, Akita RW, Sliwkowski MX. Penuel E, et al. Among authors: akita rw. J Biol Chem. 2002 Aug 9;277(32):28468-73. doi: 10.1074/jbc.M202510200. Epub 2002 May 8. J Biol Chem. 2002. PMID: 12000754 Free article.

4

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Junttila TT, et al. Among authors: akita rw. Cancer Cell. 2009 May 5;15(5):429-40. doi: 10.1016/j.ccr.2009.03.020. Cancer Cell. 2009. PMID: 19411071 Free article.

5

Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.

Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. Aguilar Z, et al. Among authors: akita rw. Oncogene. 1999 Oct 28;18(44):6050-62. doi: 10.1038/sj.onc.1202993. Oncogene. 1999. PMID: 10557094 Free article.

6

A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.

Lee H, Akita RW, Sliwkowski MX, Maihle NJ. Lee H, et al. Among authors: akita rw. Cancer Res. 2001 Jun 1;61(11):4467-73. Cancer Res. 2001. PMID: 11389077

7

Preclinical studies with Erlotinib (Tarceva).

Akita RW, Sliwkowski MX. Akita RW, et al. Semin Oncol. 2003 Jun;30(3 Suppl 7):15-24. Semin Oncol. 2003. PMID: 12840797 Review.

8

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, et al. Press MF, et al. Cancer Res. 1993 Oct 15;53(20):4960-70. Cancer Res. 1993. PMID: 8104689

9

Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL 3rd. Sliwkowski MX, et al. Among authors: akita rw. J Biol Chem. 1994 May 20;269(20):14661-5. J Biol Chem. 1994. PMID: 7514177 Free article.

10

Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display.

Ballinger MD, Jones JT, Lofgren JA, Fairbrother WJ, Akita RW, Sliwkowski MX, Wells JA. Ballinger MD, et al. Among authors: akita rw. J Biol Chem. 1998 May 8;273(19):11675-84. doi: 10.1074/jbc.273.19.11675. J Biol Chem. 1998. PMID: 9565588 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters